CEO's Message

We are very encouraged by the data supporting the development of Welichem's lead drug candidate for therapeutic application against psoriasis and eczema. This is the forerunner of a pipeline of different drugs targeted against autoimmune/ inflammatory diseases and cancer.

Our talented scientific team has identified and researched the metabolic properties of compounds that have existed in nature for millennia, but only recently has it been possible to understand how to isolate, synthesize and administer these compounds as targeted pharmaceutical drugs. As we undertake the rigorous formal testing of our WBI-1001 compound, we are excited about the prospects of bringing more effective and less expensive therapeutics to sufferers of psoriasis and eczema. Preliminary results indicated that WBI-2100 compound has a very good potential for the treatments of selected cancers.

After becoming a public company, Welichem will remain focused on creating value to its shareholders. We are committed to a strategy of timely and effective communication to shareholders and the investment community. One of the Companys top priorities is to establish strong strategic alliances with companies that can help us accelerate the path from discovery through development to delivery of our new drug leads to the commercialization.

With the commitments and support of the management and staff, I firmly believe that Welichem will be able to play an important role in the curing of autoimmune/ inflammatory diseases and cancer in the foreseeable future. We look forward to keeping you informed of our progress in addressing unmet health care needs soon.

York Yingping Guo

CEO

Welichem Biotech Inc. ("Welichem", TSX-V: WBI)